Promoting and supporting the work of pharmacists and pharmacy technicians  in supportive and palliative care
Sharing knowledge and expert practice in supportive and palliative care
Networking and peer support
Professional development
Educational events
Work in partnership and collaborate to promote the role of pharmacy in supportive and palliative care
Influence national strategies and consultations
Support and encourage research to establish best practice

Our Mission

Shared Knowledge

Sharing Knowledge And Expertise In Supportive & Palliative Care

Educational Events

Working To Develop Knowledge & Education In Supportive & Palliative Care

Networking & Peer Support

Providing Excellent Professional Networking & Peer Support

Professional Development

Working To Aid Professional Development In Supportive & Palliative Care

National Influence

Working And Influencing Supportive & Palliative Care Nationwide

Collaborate & Promote

Collaborating With The Community To Promote Supportive & Palliative Care

Members Question & Answer Forum

For hospice, hospital, community, clinical commissioning groups, research & academic pharmacy professionals working in with Palliative or Supportive Care.

Welcome Back

    • Minimum length of 5 charactersStrength indicator
    • Upload

    Create An Account

    Register for a free account with ASPCP today to gain access to the Members Q&A Forum and stay in the know about the latest events and updates in the world of palliative care

    ASPCP News

    ASPCP Conference 2018 Presentations

    For those members attending the ASPCP annual conference this Thursday in Birmingham you can access presentations from the members events page here. More presentations will be uploaded as these become available. Note that hard copies of presentations will not be...

    Pregabalin guidance in drug misuse

    This guidance sets out how to reduce the risks for people using pregabalin. Though not specifically palliative care it makes an interesting read considering the increase in use and abuse of this drug. You may find the information on tolerance and withdrawal helpful...

    World Health News

    BBC News - Health BBC News - Health

      RPS News News instance

      • GPhC council meeting 8 November 2018
        by bbellars on November 7, 2018 at 5:48 pm

        Our next council meeting takes place on Thursday 8 November 2018. Read the agenda and papers for the meeting. […]

      • GPhC responds to planned appeal on Avastin
        by mhassan on November 2, 2018 at 10:33 am

        Duncan Rudkin, Chief Executive of the GPhC said: […]

      • GPhC launches consultation on fees
        by ashleigh.farrier on November 1, 2018 at 10:30 am

        We have launched a consultation on our proposals to increase the entry and yearly renewal fees for July 2019 to July 2020. We are proposing the following increases for: pharmacists by £7 from £250 to £257 pharmacy technicians by £3 from £118 to £121 pharmacy premises by £21 from £241 to £262 This is the first time we have proposed an increase in fees since 2015. The proposed fees for pharmacy professionals are still lower than the fees charged in 2011. […]

      • Signing up to myGPhC
        by vagenjo on October 31, 2018 at 4:41 pm

        The vast majority of registrants have now successfully signed up to myGPhC.  Please check our updated troubleshooting tips or before contacting us. These resources should answer your query. We are receiving a high volume of calls into our customer contact centre, so it is likely to be quicker and easier for you to look at the information available online. […]

      • GPhC statement on supplying valproate safely to women and girls
        by bbellars on October 26, 2018 at 2:43 pm

        Valproate is a treatment for epilepsy and bipolar disorder. Children born to women who take valproate during pregnancy are at significant risk of birth defects and persistent developmental disorders. As such, it is vital that women and girls are dispensed valproate safely. The GPhC is reminding all pharmacy professionals of what they must do to ensure women and girls receive the right information about valproate and the risk of birth defects. […]